Winton Group LTD Cyma Bay Therapeutics, Inc. Transaction History

Winton Group LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$3.23 - $4.6 $57,038 - $81,231	-17,659 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$3.47 - $4.42 $61,276 - $78,052	17,659 New	17,659 $64,000
Q3 2020 Oct 30, 2020	SELL	$3.32 - $7.24 $195,063 - $425,378	-58,754 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$1.41 - $4.25 $82,843 - $249,704	58,754 New	58,754 $205,000
Q1 2020 May 11, 2020	SELL	$1.25 - $2.02 $249,226 - $402,749	-199,381 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.33 - $5.93 $265,176 - $1.18 Million	199,381 New	199,381 $391,000
Q1 2019 May 13, 2019	SELL	$8.16 - $13.42 $226,790 - $372,982	-27,793 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$6.54 - $11.74 $1,680 - $3,017	257 Added 0.93%	27,793 $219,000
Q3 2018 Nov 02, 2018	BUY	$10.88 - $14.52 $299,591 - $399,822	27,536 New	27,536 $0

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.